Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.
Curr Top Microbiol Immunol. 2021;433:77-106. doi: 10.1007/82_2021_232.
The field of vaccinology underwent massive advances over the past decades with the introduction of virus-like particles (VLPs), a supra-molecular nanoparticle vaccine platform that resembles viral structures without the ability to replicate in hosts. This innovative approach has been remarkably effective, as evidenced by its profound immunogenicity and safety. These highly desirable intrinsic properties enabled their further development as vaccines against a multitude of diseases. To date, several VLP-based vaccines have already been commercialized and many more are undergoing clinical evaluation prior to FDA approval. However, efficacious vaccines against a plethora of pathogens are still lacking, which imposes a tremendous socioeconomic burden and continues to threaten public health throughout the globe. This is especially the case for several respiratory pathogens and protozoan parasites. In this review, we briefly describe the fundamentals of VLP vaccines and the unique properties that enable these to be such valuable vaccine candidates and summarize current advances in VLP-based vaccines targeting respiratory and parasitic diseases of global importance.
过去几十年来，疫苗学领域取得了巨大进展，其中包括病毒样颗粒（VLPs），这是一种类似于病毒结构的超分子纳米颗粒疫苗平台，但其在宿主中没有复制能力。这种创新方法非常有效，其免疫原性和安全性得到了充分证明。这些理想的固有特性使它们能够进一步开发成为针对多种疾病的疫苗。迄今为止，已经有几种基于 VLP 的疫苗已经商业化，还有许多正在进行临床评估，以获得 FDA 的批准。然而，针对大量病原体的有效疫苗仍然缺乏，这给全球带来了巨大的社会经济负担，并继续威胁着公众健康。对于几种呼吸道病原体和原生动物寄生虫来说，情况尤其如此。在这篇综述中，我们简要描述了 VLP 疫苗的基本原理，以及使它们成为如此有价值的疫苗候选物的独特特性，并总结了目前针对具有全球重要性的呼吸道和寄生虫疾病的基于 VLP 的疫苗的最新进展。
